Market Snapshot
On Wednesday, October 21 2026, the shares of Odyssey Therapeutics (ticker: ODTX) advanced by 4.92 % during a 24‑hour trading interval that closed at 12:12 PM Central Europe. The current market price hovers around USD 18.99 per share on major exchanges, with a circulating supply of 47.9 million shares. These figures translate into a market capitalization of USD 867.3 million. In the previous 24 hours, approximately USD 6 million worth of Odyssey shares were exchanged.
Historically, Odyssey’s price trajectory has been volatile. Since the close of the last month, the stock has slipped ‑17.65 %. The 200‑day simple moving average rests at USD 19.74, while the 52‑week high—USD 29.05—was achieved on 4 September 2026. The 52‑week low—USD 15.10—was recorded on 8 July 2026. The recent rally has therefore moved the shares closer to the long‑term average, suggesting a potential mid‑term consolidation phase.
Recent Corporate Filing
On 20 October 2026, Odyssey Therapeutics submitted a current report detailing the successful completion of its Phase 2a induction trial for OD‑001, an oral RIPK2 scaffolding inhibitor aimed at treating ulcerative colitis. The trial results were presented at United European Gastroenterology Week and revealed that OD‑001 met its primary efficacy endpoint. Patients experienced clinically meaningful reductions in disease activity scores, improvements in endoscopic assessments, and achieved symptomatic remission. Biomarker analyses confirmed a pharmacological effect at the 20 mg twice‑daily dose, and safety data were favorable, with no serious adverse events or treatment‑related discontinuations.
Odyssey outlined a strategic roadmap to advance OD‑001 into a randomized Phase 2b monotherapy study and a Phase 2a combination trial with vedolizumab. Topline results are anticipated in the second half of 2027. The filing also highlighted the company’s broader pipeline, including programs targeting SLC15A4 and TNFR2, underscoring its commitment to developing orally administered therapies for inflammatory bowel disease and other autoimmune conditions.
Peer Performance
In the same 24‑hour window, several peer companies in the biotech and health‑tech sectors moved as follows:
| Company | Ticker | % Change | Current Price | Market Cap |
|---|---|---|---|---|
| Harrow | HROW | +1.41 % | USD 28.07 | USD 1 bn |
| Avalyn Pharma | AVLN | +5.57 % | USD 24.63 | USD 1 bn |
| Teladoc Health | TDOC | +8.38 % | USD 6.21 | USD 1 bn |
| Replimune | REPL | +3.35 % | USD 11.42 | USD 1 bn |
| Lumexa Imaging | LMRI | –0.37 % | USD 10.68 | USD 1 bn |
While most peers experienced modest gains, Teladoc Health posted the highest percentage increase, reflecting broader market optimism in digital health platforms. In contrast, Lumexa Imaging’s slight decline underscores the uneven performance within the sector.
The information presented herein reflects publicly available data and regulatory filings as of the date indicated. It is intended for informational purposes only and does not constitute investment advice.